INTRODUCTION
Androgen deficiency is a very common physical disorder that not only affects adults but can also jeopardize children's health. It is estimated that about 0.5% of children worldwide suffer from androgen deficiency. 1 For children undergoing puberty who suffer from androgen deficiency, traditional androgen replacement therapy cannot mimic their natural testosterone fluctuations, 2 and this may then lead to primary hypogonadism and altered sexual development. 3 There may, however, be other treatments available, such as stem cell therapy.
As stem cells exhibit the potential to differentiate into multiple cell types, mesenchymal stem cells (MSCs) have been used widely in the treatment of organ dysfunction. Researchers have transplanted rat adipose-derived MCSs into D-galactose-treated aging rats and found that some of the MSCs differentiated into 3-β-hydroxysteroid dehydrogenase (HSD3B1)-positive Leydig-like cells, and that testicular dysfunction was ameliorated. 4 However, Ren et al. 5 transplanted human bone marrow mesenchymal stem cells (BMSCs) into mice and found that none of the cells differentiated into Leydig-like cells. We, therefore, used human umbilical mesenchymal stem cells (HUMSCs) to treat ethane dimethanesulfonate (EDS)-induced male rat hypogonadism to study the value of HUMSCs in treating androgen deficiency.
MATERIALS AND METHODS

Isolation and culture of HUMSCs
Umbilical cords were collected aseptically with patient consent from women at full term during Cesarean section, at the Shanghai Mesenchymal stem cells from human umbilical cord ameliorate testicular dysfunction in a male rat hypogonadism model then washed with PBS 3 times. The efficiency of the CM-Dil staining was detected with a fluorescence microscope (Leica, Heidelberg, Deutschland).
Animal preparation and cell transplantation
Forty male Sprague-Dawley rats were purchased at 8 weeks of age from the Shanghai Slack Experimental Animal Center. All rats were kept under conditions of controlled temperature (24 ± 1°C), relative humidity (50%-60%), and a light/dark cycle of 12 h light/12 h dark. Standard rodent diet and drinking water were available ad libitum. All surgical procedures and postoperative care were approved by the Research Ethics Committee of Shanghai Jiao Tong University Affiliated Shanghai Children's Medical Center.
The forty rats were randomly divided into control group (twenty rats) and therapy group (twenty rats), and EDS was injected into the abdominal cavities of all forty rats at a dose of 75 mg kg −1 to destroy Leydig cell function. After 4 days of EDS injections, HUMSCs stained with CM-Dil were washed twice with PBS and incubated with 0.25% trypsin-EDTA for 1.5 min at 37°C. Cells were gently dissociated, resuspended manually, and collected in a 15 ml Corning tube. Cells were rinsed twice with PBS following centrifugation at 1000 rpm for 5 min, and finally, cells were resuspended in PBS and loaded into a 1 ml syringe for injection into the testes of adult rats. Approximately 1 × 10 6 cells in a 250 µl volume of PBS were injected into the mesenchyme of recipient testes of rats from the therapy group. The rats from the control group received 250 µl of PBS buffer. Twenty-one days after transplantation, testes from the six rats of the therapy group were tested in a random fashion using immunohistochemistry, and the testes from the six rats of the therapy group were prepared for flow cytometric sorting, which was also done in a random fashion.
Immunohistochemistry
Immunohistochemistry was performed on modified Davidson's fluid-fixed and paraffin-embedded testicular sections from grafted rats. Testicular sections were briefly deparaffinized, hydrated in a successive series of decreasing ethanol concentrations, and rinsed in distilled water. Sections were then placed in an EDTA buffer solution using a pressure cooker for 3 min for heat antigen retrieval. After rinsing in PBS, sections were blocked with 5% normal horse serum for 2 h at 37°C to prevent nonspecific binding of IgG and were subsequently incubated with a 1:100 dilution of a monoclonal anti-CYP11A1 antibody (Abcam, Cambridge, UK) at 4°C overnight. The secondary antibody was donkey anti-rabbit IgG H&L (Alexa Fluor ® 488) in a 1:2000 dilution (Abcam, Cambridge, UK), and this was used to incubate the sections for 1 h at 37°C. Nuclei were stained with DAPI. Finally, slides were dehydrated and coverslipped with neutral balsam. All slides were photographed with a fluorescence microscope.
Transplanted HUMSCs sorted by flow cytometry
Cells in the interstitial tissues of testes were isolated from rats 21 days after transplantation as described previously. 7 Briefly, rats were humanely killed by cervical dislocation, and the testes were extracted. The testes were then incubated in a centrifuge tube containing 0.03% collagenase NB4 and digested for 15 min at 37°C with shaking at 1500 rpm. The supernatant was discarded, and a fresh collagenase NB4 solution was added for a second 15-min digestion, during which time the rotational speed was lowered to 130 rpm. Cells in the supernatant were then centrifuged and resuspended in PBS. The cell suspension was then used to isolate CM-Dil-positive cells using a flow cytometry sorting instrument (MoFlo XDP, Beckman Coulter, Brea, CA, USA), and these CM-Dil-positive cells were cultured in DMEM for morphologic analysis. 
Detection of HUMSC-derived Leydig-like cells after sorting
Evaluation of testosterone concentrations
We collected blood from all forty rats at 7 days, 18 days, and 25 days after EDS injection (3 days, 14 days, and 21 days after cell transplantation), and measured the concentrations of testosterone in serum the same day that blood was collected, using a chemiluminescence assay (Shanghai Children's Medical Center).
Statistical analyses
Data were expressed as mean ± one standard deviation (s.d.) of the mean. Statistical analyses were performed using independent sample Student's t-tests to compare control and therapy groups.
RESULTS
Identification of MSC marker expression by flow cytometry
Isolated UCMSCs adhered to plastic surfaces and showed a typical spindle-shaped appearance (data not shown).
Flow cytometric analysis showed that HUMSCs were positive for CD105, CD90, and CD73, which are considered typical MSC-positive markers. Cells were negative for CD45, CD34, CD11b, CD19, and HLA-DR, which are typical markers of non-MSCs (Figure 1 ). HUMSCs were examined for expression of MSC markers; the area surrounded by the red line represents the blank control for background fluorescence, and the area surrounded by the blue line indicates signals from antibodies to human MSC markers. Cells were stained with phycoerythrin (PE), allophycocyanin (APC), peridinin-chlorophyll-protein complex-Cy5.5 (PerCP-Cy5.5), or isothiocyanate (FITC)-conjugated antibodies to indicate the following MSC markers: CD90-FITC, CD105-PerCP-Cy5.5, CD73-APC, CD34-PE, CD11b-PE, CD19-PE, CD45-PE, or HLA-DR-PE, respectively.
Morphologic assessment and immunohistochemistry of UCMSCs after transplantation
To evaluate the morphologic and histochemical changes in HUMSCs after transplantation, 21 days after transplantation, the testes of the therapy group were examined by immunohistochemistry using CYP11A1 antibody. HUMSCs, which were CM-Dil-positive cells under the fluorescence microscope, acquired a small and round Leydig cell-like appearance, and CM-Dil-positive cells were also CYP11A1-positive, indicating that they had differentiated into Leydig-like cells (Figure 2 ).
Detection and sorting of transplanted HUMSCs by flow cytometry
To examine the differentiation status of CM-Dil-stained HUMSCs after transplantation, we digested testes from rats 21 days after transplantation to acquire the cells located in the interstitium and found that these CM-Dil-positive cells were still able to proliferate (Figure 3) and showed HSD3B1-antibody staining (Figure 4) . This showed that these cells expressed HSD3B1, which indicated that UCMSCs acquired properties of Leydig cells after they were transplanted to testes from EDS-treated rats for 21 days.
Evaluation of testosterone in rat serum
Eighteen days after EDS injections, serum testosterone concentrations in the therapy group were only slightly higher (and not statistically different) compared to the control group (P = 0.643). However, after 25 days of EDS injections, serum testosterone in the therapy group was greatly augmented relative to the control group (P = 0.037) (Figure 5 ).
DISCUSSION
It is estimated that about 1 child in 200 suffers from androgen deficiency. 1 Trauma, infections, tumor growth, and radiation therapy can be the reasons for androgen deficiency in children. 8 The current clinical treatment for androgen deficiency -that of androgen replacement therapy -can cause a number of adverse reactions. 9 To avoid these side effects, pediatricians need to have at their disposal 2 Therefore, we transplanted HUMSCs into testes of EDS-treated rats to investigate their therapeutic potential, as HUMSCs have been widely used in tissue repair, and they can be induced into Leydig-like cells in vitro. 10 Our study showed that after transplantation, HUMSCs survived in an EDS-treated male rat hypogonadism model without obvious immunologic rejection. Moreover, some of the CM-Dil-marked HUMSCs expressed the Leydig cell marker CYP11A1. We sorted and cultured CM-Dil-positive HUMSCs from rat testes 3 weeks after transplantation and found that these cells were still able to proliferate and that they expressed HSD3B1. Finally, we analyzed blood samples from the therapy and control groups, and the results showed that the therapy group's serum testosterone levels were higher than in the control group (P = 0.037). Our results suggest that HUMSCs are able to differentiate into Leydig-like cells with normal function.
EDS, as an alkylating agent, is able to specifically eliminate adult Leydig cells from rat testes. The elimination of adult Leydig cells is then normally followed by a Leydig cell regeneration process, which is similar to the Leydig cell differentiation process observed for human puberty. 11 During the process of Leydig cell regeneration, and as a result of low testosterone, the levels of other hormones and cytokines may be upregulated. 12 For example, luteinizing hormone has been used to induce HUMSCs into Leydig-like cells in vitro, 13 nerve growth factor can promote the regeneration and differentiation of Leydig cells, 14 and protein kinase inhibitor β may interact with the catalytic subunit of cAMP-dependent protein kinase and act as a competitive inhibitor, thus stimulating cell growth and androgen secretion. 15 In addition, as a cell that is important in the construction of the testicular microenvironment, Sertoli cells can promote Leydig cell differentiation via the secretion of cellular factors such as epidermal growth factor, 16 insulin-like growth factors-1, 17 and platelet-derived growth factor. 18 We hypothesize that the combined effects of the upregulation of cellular factors and the testicular microenvironment can induce HUMSCs into Leydig-like cells.
Our study showed that transplanting HUMSCs into EDS-treated rats promoted the recovery of blood testosterone levels back to normal. The flow cytometric analyses indicated that some of the HUMSCs also expressed HSD3B1, and these HSD3B1-positive cells may be considered functional Leydig-like cells involved in the accelerated recovery of serum testosterone. However, it should be noted that undifferentiated MSCs might also promote the regeneration of Leydig cells. It has been reported that MSCs are able to secrete various cellular factors and adhesive molecules, including vascular endothelial growth factor, basic fibroblast growth factor, hepatocyte growth factor, and insulin-like growth factor-I that exert beneficial paracrine effects on surrounding cells. [19] [20] [21] These cellular factors can then promote the regeneration of Leydig cells and enhance their functions. 17, 18, 22 In the present experiment, transplanted HUMSCs may have released or promoted the release of certain factors that guided the regeneration of Leydig cells. HUMSCs, compared with BMSCs, possess a higher proliferative potential, and HUMSCs are more capable of differentiating into Leydig cells. 6 In our study, we transplanted MSCs from humans instead of rats because some researchers have claimed that human BMSCs do not differentiate into Leydig cells in mouse testes. 5 This raised the question of whether MSCs are able to change into Leydig cells or differentiated MSCs. The matter has not yet been resolved because of technical problems that may cause a failure of differentiation. To answer this question, we used HUMSCs instead of rat MSCs, and we marked HUMSCs with CM-Dil, which is a good cell tracer that is not only unaffected by cell proliferation and differentiation 23 but is also able to keep cells stained for longer than 4 weeks in vivo. 24 We also did not find any obvious immunologic rejection after the transplantation. As an immunologically privileged organ, the testis contains few immunocytes, and HUMSCs do not express the major histocompatibility complex (MHC) class II (HLA-DR) antigens. [25] [26] [27] Previous studies have shown that umbilical mesenchymal stem cells are still viable and not rejected 4 months after transplantation as xenografts, without the need for immune suppression; 28 this also proved the feasibility of heteroplastic transplantation using HUMSCs.
In our study, although we did not find cells with double nuclei, we were still not able to rule out the possibility of cellular fusion between HUMSCs and recipient testicular Leydig cells or their progenitor cells. In addition, as we did not determine the origin of the cells staining positive for HSD3B1 by double-staining for human nuclear antigen, it is possible that not all of the CM-Dil-labeled cells were HSD3B1 positive originated from human tissues. However, we believe that the elevation in serum testosterone still highlights the value of using MSCs in the treatment of androgen deficiency.
CONCLUSION
HUMSCs can promote recovery of serum testosterone levels in EDS-treated rats via differentiation into normally functioning Leydig-like cells. Based on our results, HUMSCs may constitute a promising therapy for the treatment of both young and old male hypogonadism patients.
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